Taiwanese (TAIEX) Pharma Industry Analysis
- 7D-0.4%
- 3M-1.5%
- 1Y13.6%
- YTD-2.5%
Over the last 7 days, the Pharma industry has remained flat, although notably Bora Pharmaceuticals gained 7.7%. As for the the longer term, the industry is up 14% over the past 12 months.
Industry Valuation and Performance
Has the Taiwanese Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE |
|---|---|---|---|---|
| Tue, 18 Jan 2022 | NT$376.1b | NT$76.7b | NT$8.5b | 19x |
| Thu, 16 Dec 2021 | NT$392.1b | NT$76.7b | NT$8.5b | 18.4x |
| Sat, 13 Nov 2021 | NT$364.5b | NT$76.1b | NT$7.9b | 17.3x |
| Mon, 11 Oct 2021 | NT$348.0b | NT$76.0b | NT$10.7b | 18.9x |
| Wed, 08 Sep 2021 | NT$354.1b | NT$76.0b | NT$10.7b | 18.8x |
| Fri, 06 Aug 2021 | NT$368.8b | NT$76.0b | NT$10.7b | 21.3x |
| Mon, 10 May 2021 | NT$358.3b | NT$74.2b | NT$12.5b | 18.7x |
| Sun, 31 Jan 2021 | NT$300.3b | NT$72.4b | NT$8.6b | 17.1x |
| Wed, 04 Nov 2020 | NT$356.2b | NT$71.7b | NT$6.3b | 18.5x |
| Sat, 08 Aug 2020 | NT$328.7b | NT$70.9b | NT$5.6b | 20.6x |
| Fri, 01 May 2020 | NT$231.6b | NT$70.2b | NT$1.8b | 22.3x |
| Mon, 03 Feb 2020 | NT$224.7b | NT$69.7b | NT$1.3b | 21.6x |
| Thu, 07 Nov 2019 | NT$231.9b | NT$69.1b | NT$5.9b | 21.2x |
| Wed, 31 Jul 2019 | NT$228.5b | NT$73.2b | NT$7.4b | 21.6x |
| Sat, 04 May 2019 | NT$226.8b | NT$78.9b | NT$7.8b | 21.4x |
| Tue, 05 Feb 2019 | NT$217.6b | NT$82.6b | NT$8.6b | 19.1x |
19.1x
Current Industry PE: Investors are relatively neutral on the industry at the moment, considering it's trading close to its 3-year average PE ratio of 20.1x. It appears they believe that earnings will grow in-line with historical growth rates.
Past Earnings Growth: The earnings for companies in the Pharmaceuticals industry have remained mostly flat over the last three years, while revenues for these companies have declined 2.4% per year. This means that the cost of doing business could be reducing since sales have declined but profits have remained steady.
Industry Trends
Which industries have driven the changes within the Taiwanese Pharma industry?
| Pharma | -0.41% | |
Industry PE: Investors are most optimistic about the Pharma industry, which is trading close to its 3-year average PE ratio of 20.1x. This is likely because analysts are expecting annual earnings growth of 34%, which is higher than its past year's earnings decline of 11% per year.
Forecasted Growth: Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 34% over the next 5 years. This is better than its past earnings decline of 11% per year.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 6472 Bora Pharmaceuticals | NT$182.00 | 10.6% +NT$1.2b | 44.5% | PE11.8x | |
| 6535 Lumosa Therapeutics | NT$38.55 | -0.8% NT$378.5m | 26.0% | PE18.5x | |
| 6576 Foresee Pharmaceuticals | NT$115.00 | 2.7% +NT$352.7m | 39.4% | PS32.2x | |
| 6634 Sinew Pharma | NT$82.30 | 2.2% +NT$124.2m | 3.9% | PS1030.9x | |
| 1760 Panion & Bf Biotech | NT$79.30 | 1.7% +NT$111.5m | 0.9% | PE46.2x |